Augmented-Reality CTA Plus Angiography vs Angiography Alone for Guiding PCI in Coronary Lesions - Randomized Study (AR-PCI)

May 19, 2018 updated by: Paul Knaapen

On-Site Augmented-Reality Computed Tomography Plus Angiography Versus Angiography Alone for Guiding Percutaneous Coronary Intervention in Native Coronary Lesions - Randomized Study

The purpose of this study is to compare revascularization strategy and its immediate results after augmented-reality computed tomography angiography (CTA) guided vs. standard angiography guided percutaneous coronary intervention (PCI) in native coronary lesions.

Study Overview

Detailed Description

While stand-alone angiography is the first-line imaging modality for guidance of PCI, it has some inherent limitations which may result in suboptimal stent placement related to residual reference segment disease and stent underexpansion. Coronary CTA, on the other hand, can provide reliable measurements of the vessel size and lesion length as well as the visualization of the morphological features of coronary plaque, and has been suggested as potentially valuable for changing PCI technique. The AR-PCI trial has been designed as a single-center, investigator initiated and investigator sponsored, randomized (1:1), controlled, prospective clinical trial. It is hypothesized that the review of CTA datasets using augmented-reality glass in the catheterization laboratory could influence PCI treatment strategy and its immediate results by more adequate lesion coverage with less residual disease and better stent expansion as compared to traditional angiography-guided PCI alone.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Maksymilian P. Opolski, MD, PhD
  • Phone Number: +48501444303
  • Email: m.opolski@vumc.nl

Study Locations

    • De Boelelaan 1117
      • Amsterdam, De Boelelaan 1117, Netherlands, 1081 HV
        • Recruiting
        • VU University Medical Center Amsterdam
        • Contact:
          • Maksymilian P. Opolski, MD, PhD
          • Phone Number: +48501444303
          • Email: m.opolski@vumc.nl
        • Sub-Investigator:
          • Maksymilian P. Opolski, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients with documented obstructive CAD defined as the presence of at least 1 stenosis ≥70% in a native coronary artery in whom PCI is considered based on clinical grounds

Exclusion Criteria:

  • refusal or inability to provide written informed consent
  • subjects in whom the quality of coronary CTA is insufficient
  • bifurcation lesions, by which strategies other than a single cross-over stent technique are anticipated
  • left main coronary artery stenosis
  • chronic total occlusion
  • in-stent restenosis
  • chronic renal failure (estimated glomerular filtration rate <30 ml/min)
  • known allergy to contrast
  • untreated hyperthyroidism
  • pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Angiographic guided PCI
Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
Experimental: CTA guided PCI
CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stent length
Time Frame: 1 day
Length of the stented segment
1 day
Predicted stent diameter
Time Frame: 1 day
Predicted final stent diameter according to a compliance chart
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nominal stent diameter
Time Frame: 1 day
Nominal diameter of the implanted stent
1 day
Number of stents
Time Frame: 1 day
Total number of stents
1 day
Predilation
Time Frame: 1 day
Balloon predilation for lesion modification
1 day
Postdilation
Time Frame: 1 day
Balloon postdilation for stent expansion
1 day
Maximal balloon pressure
Time Frame: 1 day
Maximal balloon pressure applied during PCI
1 day
Maximal balloon diameter
Time Frame: 1 day
Maximal balloon diameter applied during PCI
1 day
Stent-edge dissection
Time Frame: 1 day
Stent-edge dissection by coronary angiography
1 day
Post-procedural residual diameter stenosis
Time Frame: 1 day
Post-procedural residual diameter stenosis by 3D QCA
1 day
Post-procedural residual area stenosis
Time Frame: 1 day
Post-procedural residual area stenosis by 3D QCA
1 day
Post-procedural minimum lumen diameter
Time Frame: 1 day
Post-procedural minimum lumen diameter by 3D QCA
1 day
Post-procedural minimum lumen area
Time Frame: 1 day
Post-procedural minimum lumen area by 3D QCA
1 day
Post-procedural lumen diameters at the reference segments
Time Frame: 1 day
Post-procedural lumen diameters at the reference segments by 3D QCA
1 day
Post-procedural lumen areas at the reference segments
Time Frame: 1 day
Post-procedural lumen areas at the reference segments by 3D QCA
1 day
Post-procedural volume of the stented segment
Time Frame: 1 day
Post-procedural volume of the stented segment by 3D QCA
1 day
Post-procedural volume of the reference segments
Time Frame: 1 day
Post-procedural volume of the reference segments by 3D QCA
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 25, 2018

Primary Completion (Anticipated)

September 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

May 8, 2018

First Submitted That Met QC Criteria

May 8, 2018

First Posted (Actual)

May 21, 2018

Study Record Updates

Last Update Posted (Actual)

May 22, 2018

Last Update Submitted That Met QC Criteria

May 19, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Angiographic guided PCI

3
Subscribe